Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company. We believe ...

We have used Biotrue Hydration Boost Rehydrating ... Over.all, we highly recommend the Sensitive Eyes Contact Lens Solution by Bausch + Lomb for anyone with sensitive eyes who wears soft contact ...

Bausch Health turned down recent debt-restructuring proposals from bondholders as it explores a sale of its Bausch + Lomb vision care subsidiary that could bring in billions of dollars to pay ...

said that Bausch can endorse whoever he pleases, adding that it's important for the elected council members to all be able to work together. "I don't mind having opposition, but we need to work ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Global contact lens supplier Bausch + Lomb (BLCO +7%) is seeing significant gains today after FT.com reported that private equity firms TPG and Blackstone (BX) are mulling a joint bid for the company.

Private equity giants TPG and Blackstone have joined forces to submit a joint bid for eyecare company Bausch + Lomb, Financial Times reported citing sources familiar with the development. If ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.